

OTC Markets

Joining said day is Dr Eric Leire the CEO of Genflow Biosciences that on our OTCQB Venture Market under the ticker GENFF. Genflow Biosciences is a UK based biotech company dedicated to the development and commercialization of novel therapeutics targeting aging in dogs and humans. Eric thanks for much for joining us today here in New York.

Dr. Eric Leire

thank you very much Cecilia.

OTC Markets

So, Eric to start tell us a bit about your professional background and how you got involved with ginflow.

Dr. Eric Leire

As a CEO of Biotech companies. No surprise I'm a medical doctor I have an MBA from northwestern and Astro Se Paris in France um French American dual citizen. Um I I will define myself as a. Outcore medical doctor reference you know evidence-based medicine and train as a nephologist kidney transplantation I moved to Immunoropian Genropy ah early in my career and I've been where I've been CEO of Biotech companies for the last twenty years private listed companies Denmark US Nasdaq OTC mostly in immuno oncology.

I moved recently to Genflow longevity company because I realized that yes as doctors we've done fantastic job at increasing the lifespan the last hundred years lifespan progressed from 40 years in average to 80 years we got a second life. Fantastic unfortunately, most of us we waste that second life fighting the age related disease and this should not happen. So longevity is not only extending the duration of life but having a second life that enjoyable not a second life. You fight you spend fighting against cancer nondratic disease.

Diabetics stroke we understand the drivers of biology. We start to unveil the mechanism of aging we understand that we can act on those drivers. We identify some genes that are age related regulators and that's what trigger the creation of Genflow and my decision to leave immune-oncology after a little bit of 20 years in immune-oncology. To move to our longevity.

OTC Markets

So with this philosophy is there an economic and social demand for this aging

you know slowing the aging process?

Dr. Eric Leire

The context is demographic. Ah. Everyone and people listen to us I've been like me used to a demographic like a pyramid a pyramid with a large base of young people supporting a small group of all people. This is not the case and worldwide. Not only in Europe us developed countries but everywhere in the world who for the first time in human history. We faced a totally different demographic structure. We have now more people age 65 that people under 5.

It's the first time in human history of course with the cost of age-related disease the treatment of all those ageal related disease the cancer the notative disease you know the cost of an Alzheimer cost of. Of Parkinson the cost of treating cancer. All that is increasing, and this is not sustainable.

OTC Markets

Economically so and what and explain I guess you just went into that a little bit the age-related diseases. But um, are there any kind of diet related you know advantages that may be different.

Dr. Eric Leire

Countries and worldwide have in in in you know coordination with aging interesting question but I will clarify age related disease. Typically when we talk about edge related disease I'm attending to moral conference hour. Can we fight age related disease but we. Typically talk about the 4 big disease that costs the society a lot type 2 diabetes and the complication dialysis and cancer all the neurogenerative disease and to cardiovascular events like stroke. All those are super costly and that's what costs really the society that that's where the big costs are but age relative disease should be defined a little bit more broader more broad. Broadly um, in fact, when we age.

We accept that our cognitive functions are not as good as before or I lost again my phone I lost again my keys when I go up the stairs I'm out of price after 3 5 floors and I was not like that we accept that. If we go to our cardiologist and we say I'm fine. But I'm going for a checkup. Um, you just take your blood pressure. Your blood pressure is high. Um, first thing you will say said it's. Not a disease obviously because you wear no, you had no symptom but this a risk factor and we need to treat that as a risk factor and it will give you drug that will lower your blood pressure I'm fine now when you have ah aging. Ah. Your doctor if you complain that you are out of price that your immune system is not as good and

I'm not even talking about covid where all people were dying when young were asymptomatic but when you have those complaints your doctor is most likely to say done. it's aging you have to accept it it's a fatality and in fact it's not a fatality we understand the biology and we can act on that. So if our cardiologists were saying oh you have a blood pressure but it's not a disease just a risk factor.

You have to accept that it's the way you know it's happens you have high blood pressure I don't care come back when you do a stroke when you my myocardi infection then I will treat you said the guy is crazy but when you come to aging we accept it. And that's why those interview interviews are important because we need to change the mindset of people science progressed super fast. The mindset of all of us progress gradually slowly and we so used to. Okay, it's aging I accept it. There's nothing I can do now I come back to your first question about diet. Yes, um, diet is it working. It's a tricky question because you know diet everyone has ah an opinion on diet and you have. People said no protein no carb, no things. Okay, the lifestyle changed for aging among the lifestyles. You have 4 big pillars. You have exercise diet sleep and social interaction. By far. Unfortunately, it's not diet the number one. It's exercise is so far the most powerful tool in terms of just change in lifestyle that we have our disposal to delay aging. So ah.

That means you don't need to do a marathon typically you do zone 2 cardio that means you jog when you can talk. It's chugging a little bit fast but you can go swimming. You can go biking. You can. This kind of exercise when it's done regularly and it doesn't have to be done like you don't have to spend 4 hours per day but regularly that's what's most important so it has to be done. All year if she said. Okay oh I will be on vacation I will play tennis like crazy 8 hours that will not invite your aging. But if you exercise regularly? Yes now diet second diet is interesting. Calorie restriction is. Most playful. It's not easy to implement. Um, it has to be a change in lifestyle you cannot say I go I'm x pounds and I need to get.

20% lower weight. That's not the way it works. You need to decide. This is the diet I will keep for the rest of my life and it's consistency again. That's the key things. So it's not getting your. Your weight down and then doing nothing. It's just changing your diet that means you need to find something that's acceptable for you where you said okay socially I can accept it I can have France and because food has a lot of. Part of social interaction and the force pillar was social interaction very important so it has to be something you can sustain for the rest of your life with pleasure and pleasure is a very important part of our life. So if it's not pleasant. It's a. Bad diet for you? Okay, ah personally I do intermittent fasting because there's a benefit with intermittent fasting. So I eat on an 8 hour window

it's me I like it. It's easy. It allows me to have social interaction I just keep the breakfast and um with this kind of 8 hour window where I eat that give me the your body to have an easy calorie restriction. So I don't I don't go.

2 over the board in terms of calorie intake again. Unfortunately the physics works and calorie in calorie out. It works a lot of course if you combine with exercise you can have more calories because you instead of two thousand calories you will spend if you do ah.

1 hour of exercise of running or weightlifting then that's ah, that's an increase in your basic metabolism sleep in terms of life of life style change is extremely important.

All those factors are interrelated when I said diet for example and sleep are strongly related if you want to have a good sleep 7 hours ah I will recommend to read the book from walker is a world specialist. He's an American guy wrote excellent book on sleep. Ah sleep is extremely important. Ah sleep is very strange. We are not reproducing. We are vulnerable. Doing nothing. We don't have consciousness and it stays in the evolution. It's not something that has been wiped out from the evolution when it's so dangerous for us. So there's a reason and every. Living organism every marble sleeps. So. There's not one animal I don't sleep and I feel well so sleeping very important our age diet. 1 of the best things you can do to improve your sleep is not to eat too much in the evening. So typically avoid to have a big meal 3 hours 4 hours before you go to bed regular time quality sleep is important seven eight hours typically some people said 60 s okay if you were older.

There's a debate but where there's no debate was a huge consensus is the regularity if you can go to bed at 11 p M wake up at 7 for example, that's what I do 8 hours perfect but it's eleven seven and if you can keep the same schedule of sleep during the week and the weekend that's perfect. A lot of people said okay I don't sleep during the week because work because travel and but I will recuperate during the weekend. Doesn't work. You don't recuperate. it's a fallac so it's all about consistency and the first one. It's a log and is social interaction again. Social interaction is very important. It's linked with the others. It's linked with exercise. For example, ah and your diet and your diet when you discuss with people doctors gerts who works on old people. The trigger. For the things what things are going bad when you're older is when you start losing muscles when you start losing muscles. You start losing mobility you increase your chance of diabetes of norative disease of cancer of.

Cardiovascular event of course. Ah, and so also because you have less probability you have less social interactions and that's usually the beginning of the end. It's you lose muscle because you don't exercise because you don't eat enough protein. See general election and that's enough I seek it so low that was very very comprehensive.

OTC Markets

So Eric you mentioned Nash explain what that is and why it's important.

Dr. Eric Leire

Sorry Nash is Theron form. Non-alcoholic stato epipaateis it's liveal disease progressing it start with. Fat accumulation to get a fat uever then there's inflammation with fibrosis when the fibrosis is installed. You have cyrusis and then it evolved to epato carcinoma. It's a silent disease but it's. Huge problem to come estimated 32000000 with Nash in the in the world 16000000 in the us it's becoming the leading cause of liver transplant. There's no therapy. It's quite interesting to develop a drug there because. There's because there's a huge met need both the FDA and the European agencies issues guidelines for a acceleratory development pass ways. So you can get shortcut to be faster on the market because there's a huge need. Know this there will be a large number of Americans who will not be able to get a ler transplant and there's a huge need for a product. Why are we going there. We are longevity. Why we're not getting a product that makes you leave 150 and.

Being able to run a marathon because the FDA. Yeah, and the European agency do not consider aging as a disease as we mentioned before and so there's no possibility to develop you have to develop on agerolic disease lever is quite interesting. Because Liver is one of those rare organs we can regrow. Um, we're not salamander if you lose a harm it. You will not regrow 1 We regrow our nails. We grow our hair. But if you give up of your lever so Liveber will. Regrow so you can rejuven it so we can take this old fibrosis liver and bring it to a young functional state and that's quite interesting. Our 6 that the gene-based therapy based on the zero six variant we found in Centinarian as amazing properties in term ofever. Um, what's interesting. It has properties on every step of the progression of the disease. It has. An impact on the stetosis. The accumulation of fat it changed the profile of the fat deposition. It's anti-inflammatory it has an anti fibrotic effect which is extremely important. It has an antitumour effect. Also.

So at every step of the disease that it's an evolution disease. It's active so we can reverse that stage functional. That's quite exciting the few drugs that are in development are even. Try to tackle these problems through the anti fibrosis

alone or the antitumour alone or the ah and the thd deposition but to have the possibility to act on the entire spectrum of the evolution is quite unique and that's why we think we have a very good shot. We'll be ready to start the clinical trial in eighteen months with our first meeting with the European agency fag and we presented the first. Results of our preclinical trial and they've been very nice to let us free to skip healthy volunteers and to start directly with a fine phase one two when you develop a draw. You're supposed to start with. Ah, phase one it healthys you volunteers when you define those and you don't therefore demonstrate any kind of efficacy. You just demonstrate that the drug is safe unfortunately and of phase one. It's yes you first in-man. But for the investors.

Ah, that doesn't coincide with a huge increase in the valuation of the company. It just said the drug is safe but this glass of water is safe that doesn't make these glass of water very valuable. What makes a drug valuable is the first signal if you can see inhuman. We have efficacy in mice in mice and human are very different so it should work. But what you need to see to see the huge increase in valuation is a significancy in human and in eighteen months we'll be. Able to start directly with this with this trial with Nash patients. So that's exciting.

OTC Markets

Um, so you just joined OTCQB and with your home country market is in the UK on the LSE. Um, you know you cross-trade now here in the US, tell US about your goals for expanding your US investor base.

Dr. Eric Leire

We listed in London in fact, our air and d is based in Brussels. Why because we get very low writing costs and we get subsidies from the government 70% of our r and d is non diluting cash r and d grants. So perfect. All the investors will understand the benefit. We are our headquarter is in UK because we listed on London that the best exchange in Europe and there was no longevity companies in listed in Europe so there was an open field. We capture it. Um. Now London has limited liquidity and we've been listed for 2 years, and we want to expand we investor based with OTCQB. There's also differential in terms of risk aversion between the UK and US.

In the US an early-stage biotech can get higher valuation than in Europe and we expect to see our share price increase. Ah in the u with treading in the US. Um, why was it important to list in the UK. Because we wanted it to be on the vaddock screen of pharma and being the first longevity listed in Europe put us on that radock screen I we're still in preclinical. We will start our clinical trial in Nash. I hope we can talk about that. That's very interesting and it's made surprising as

we talk about longevity that all of a sudden we talk. We talk about all liver disease. But um, it was important to be on the radar screen of. Pharma because pharma is totally absent of longevity. It's not regulated by the FDA. It's not regulated by the European Agency Medicine agency so therefore they don't do research. It's only biotech like mine. Like unity like Genflow. There's a lot of biotech because we understand the biology so a lot of people. It's exciting and it's new science and we can have very effective tools coming. So everybody's going there but it's only biotech companies.

We see some changes which show consider aging as a risk factor. It's just a code nine. It's a code that it's given to so aging is considered as a disease and a risk factor as soon as the FDA yeah is considering aging as a risk factor or a disease or the European agency. Will be a massive wave of acquisition from pharma a little bit of what I saw in my pasar and immuno-oncology where people think oh working on the immune system to treat cancer is ridiculous. It will never work and no one was working on it and then boom. It arrives and then pharma just acquire the companies and its strategic acquisition with crazy price and that what will happen. It will be our exit so it was very important to be on the radar screen of the us being on OTCQB of course. Contribute to that.

OTC Markets

Well Eric it's been a pleasure speaking with you and here in our offices downtown lower Manhattan okay. And so Genflow Biosciences trades out of the symbol GENFF on our OTCQB Venture Market.

**This is an autogenerated transcript and may contain typos.*